This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hendrix, N. D. Articles by Cho, K. R. Search for Related Content PubMed PubMed Citation Articles by Hendrix, N. D. Articles by Cho, K. R.

Fibroblast Growth Factor 9 Has Oncogenic Activity and Is a Downstream Target of Wnt Signaling in Ovarian Endometrioid Adenocarcinomas

Departments of ¹ Pathology, ² Pediatrics and Communicable Diseases, and ³ Internal Medicine, and ⁴ Comprehensive Cancer Center, University of Michigan Medical School, Ann Arbor, Michigan and ⁵ Karmanos Cancer Center of Wayne State University, Detroit, Michigan

Requests for reprints: Kathleen R. Cho, Department of Pathology, University of Michigan Medical School, 5401 LSI, 210 Washtenaw Avenue, Ann Arbor, MI 48109-2216. Phone: 734-764-1549; Fax: 734-647-7950; E-mail: kathcho{at}umich.edu.

Wnt signaling plays a key role in development and adult tissues via effects on cell proliferation, motility, and differentiation. The cellular response to Wnt ligands largely depends on their ability to stabilize ß-catenin and the ability of ß-catenin to bind and activate T-cell factor (TCF) transcription factors. Roughly 40% of ovarian endometrioid adenocarcinomas (OEA) have constitutive activation of Wnt signaling as a result of oncogenic mutations in the ß-catenin protein or inactivating mutations in key negative regulators of ß-catenin, such as the adenomatous polyposis coli and Axin tumor suppressor proteins. We used oligonucleotide microarrays to identify genes of which expression was activated in OEAs with ß-catenin dysregulation compared with OEAs lacking Wnt/ß-catenin pathway defects. Using microarray and quantitative PCR-based approaches, we found that fibroblast growth factor (FGF9) expression was increased >6-fold in primary OEAs with Wnt/ß-catenin pathway defects compared with OEAs lacking such defects. Evidence that ß-catenin and TCFs regulate FGF9 expression in several epithelial cell lines was obtained. We found FGF9 was mitogenic for epithelial cells and fibroblasts and FGF9 could stimulate invasion of epithelial and endothelial cells through Matrigel in transwell assays. Furthermore, FGF9 could promote neoplastic transformation of the E1A-immortalized RK3E epithelial cell line, and short hairpin RNA–mediated inhibition of endogenous FGF9 expression in the OEA cell line TOV112D, which carries a ß-catenin mutation, inhibited neoplastic growth properties of the cells. Our findings support the notion that FGF9 is a key factor contributing to the cancer phenotype of OEAs carrying Wnt/ß-catenin pathway defects. (Cancer Res 2006; 66(3): 1354-62)

This article has been cited by other articles:

				P. D. Williams, S. Cheon, D. M. Havaleshko, H. Jeong, F. Cheng, D. Theodorescu, and J. K. Lee Concordant Gene Expression Signatures Predict Clinical Outcomes of Cancer Patients Undergoing Systemic Therapy Cancer Res., November 1, 2009; 69(21): 8302 - 8309. [Abstract] [Full Text] [PDF]

				R. Meyer, V. Fofanov, AnilK. Panigrahi, F. Merchant, N. Zhang, and D. Pati Overexpression and Mislocalization of the Chromosomal Segregation Protein Separase in Multiple Human Cancers Clin. Cancer Res., April 15, 2009; 15(8): 2703 - 2710. [Abstract] [Full Text] [PDF]

				D. S.P. Tan, M. B.K. Lambros, S. Rayter, R. Natrajan, R. Vatcheva, Q. Gao, C. Marchio, F. C. Geyer, K. Savage, S. Parry, et al. PPM1D Is a Potential Therapeutic Target in Ovarian Clear Cell Carcinomas Clin. Cancer Res., April 1, 2009; 15(7): 2269 - 2280. [Abstract] [Full Text] [PDF]

				N. Hempel, T. How, S. J. Cooper, T. R. Green, M. Dong, J. A. Copland, C. G. Wood, and G. C. Blobe Expression of the type III TGF-{beta} receptor is negatively regulated by TGF-{beta} Carcinogenesis, May 1, 2008; 29(5): 905 - 912. [Abstract] [Full Text] [PDF]

				R. Rajhans, S. Nair, A. H. Holden, R. Kumar, R. R. Tekmal, and R. K. Vadlamudi Oncogenic Potential of the Nuclear Receptor Coregulator Proline-, Glutamic Acid-, Leucine-Rich Protein 1/Modulator of the Nongenomic Actions of the Estrogen Receptor Cancer Res., June 1, 2007; 67(11): 5505 - 5512. [Abstract] [Full Text] [PDF]

				P.-C. Chuang, H. S. Sun, T.-M. Chen, and S.-J. Tsai Prostaglandin E2 Induces Fibroblast Growth Factor 9 via EP3-Dependent Protein Kinase C{delta} and Elk-1 Signaling Mol. Cell. Biol., November 15, 2006; 26(22): 8281 - 8292. [Abstract] [Full Text] [PDF]